Cadrenal Therapeutics signs collaboration with Abbott to support Phase 3 LVAD trial of tecarfarin

Cadrenal Therapeutics, Inc.

Abbott will share LVAD data from MOMENTUM 3 and ARIES HM3 trials for TECH-LVAD trial design.
Abbott to assist with biostatistics, site selection, patient enrollment, and medical science liaison.
Cadrenal is regulatory sponsor; tecarfarin-related IP owned by Cadrenal, device-related IP by Abbott.
Phase 3 TECH-LVAD trial compares tecarfarin vs warfarin in HeartMate 3 LVAD patients with open-label extension.
No upfront or milestone payments disclosed; Cadrenal still pursuing additional funding partnerships for the study.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.